Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
"It's been a very liberating experience": doxycycline post-exposure prophylaxis (doxy-PEP) for STI prevention and experiences with sexual pleasure by men who have sex with men (MSM).
Perkins R, Fredericksen RJ, Christopoulos KA, Beima-Sofie K, Cohen SE, Dombrowski JC, Dright A, Gardner S, Kohler P, Luetkemeyer AF, Pintye J, Celum C. Perkins R, et al. Among authors: luetkemeyer af. Sex Transm Dis. 2025 Jul 10. doi: 10.1097/OLQ.0000000000002220. Online ahead of print. Sex Transm Dis. 2025. PMID: 40637301
Another Tool for the Sexual Health Toolkit: US Health Care Provider Knowledge and Attitudes About Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections Among Men Who Have Sex With Men.
Perkins R, Beima-Sofie K, Christopoulos K, Cohen SE, Dright A, Dombrowski JC, Gougougui A, Kohler P, Luetkemeyer AF, Pintye J, Celum C. Perkins R, et al. Among authors: luetkemeyer af. Sex Transm Dis. 2025 Mar 1;52(3):129-134. doi: 10.1097/OLQ.0000000000002095. Epub 2024 Oct 31. Sex Transm Dis. 2025. PMID: 39481014
Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.
Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, Malinski C, Perkins R, Nasser M, Lopez C, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C; DoxyPEP Study Team. Luetkemeyer AF, et al. N Engl J Med. 2023 Apr 6;388(14):1296-1306. doi: 10.1056/NEJMoa2211934. N Engl J Med. 2023. PMID: 37018493 Free PMC article. Clinical Trial.
Ethical Considerations in Implementing Doxycycline Postexposure Prophylaxis for the Prevention of Bacterial Sexually Transmitted Infections.
Sugarman J, Taylor HA, Bachmann LH, Barbee LA, Cahill S, Celum C, Cohen SE, Faden RR, Luetkemeyer AF, Mayer KH, Mena L, Mermin J, Upshur R, Aral S. Sugarman J, et al. Among authors: luetkemeyer af. Sex Transm Dis. 2024 Mar 1;51(3):135-138. doi: 10.1097/OLQ.0000000000001907. Epub 2023 Dec 6. Sex Transm Dis. 2024. PMID: 38079243 Free PMC article. No abstract available.
Doxycycline as Postsexual Exposure Prophylaxis: Use, Acceptability, and Associated Sexual Health Behaviors Among a Multi-Site Sample of Clinical Trial Participants.
Fredericksen RJ, Perkins R, Brown CE, Cannon C, Lopez C, Cohee A, Dombrowski JC, Cohen S, Malinski C, Powell M, Luetkemeyer AF, Celum C, Christopoulos K. Fredericksen RJ, et al. Among authors: luetkemeyer af. AIDS Patient Care STDS. 2024 Apr;38(4):155-167. doi: 10.1089/apc.2023.0289. AIDS Patient Care STDS. 2024. PMID: 38656217 Free PMC article. Clinical Trial.
Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends.
Sankaran M, Glidden DV, Kohn RP, Nguyen TQ, Bacon O, Buchbinder SP, Gandhi M, Havlir DV, Liebi C, Luetkemeyer AF, Nguyen JQ, Roman J, Scott H, Torres TS, Cohen SE. Sankaran M, et al. Among authors: luetkemeyer af. JAMA Intern Med. 2025 Mar 1;185(3):266-272. doi: 10.1001/jamainternmed.2024.7178. JAMA Intern Med. 2025. PMID: 39761052
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, McQuarrie LJ, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Rouphael NG, et al. Among authors: luetkemeyer af. J Infect Dis. 2023 Dec 20;228(12):1662-1666. doi: 10.1093/infdis/jiad323. J Infect Dis. 2023. PMID: 37561027 Free PMC article. Clinical Trial.
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case.
Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, El Sahly HM, Jain MK, Mehta AK, Wolfe CR, Gomez CA, Beresnev T, Mularski RA, Paules CI, Kalil AC, Branche AR, Luetkemeyer A, Zingman BS, Voell J, Whitaker M, Harkins MS, Davey RT Jr, Grossberg R, George SL, Tapson V, Short WR, Ghazaryan V, Benson CA, Dodd LE, Sweeney DA, Tomashek KM. Ortega-Villa AM, et al. Open Forum Infect Dis. 2023 May 27;10(6):ofad290. doi: 10.1093/ofid/ofad290. eCollection 2023 Jun. Open Forum Infect Dis. 2023. PMID: 37383244 Free PMC article.
Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
Lake JE, Taron J, Ribaudo HJ, Leon-Cruz J, Utay NS, Swaminathan S, Fitch KV, Kileel EM, Paradis K, Fulda ES, Ho KS, Luetkemeyer AF, Johnston CD, Zanni MV, Douglas PS, Grinspoon SK, Lu MT, Fichtenbaum CJ; REPRIEVE Trial Investigators. Lake JE, et al. Among authors: luetkemeyer af. AIDS. 2023 Nov 15;37(14):2149-2159. doi: 10.1097/QAD.0000000000003671. Epub 2023 Jul 27. AIDS. 2023. PMID: 37503623 Free PMC article. Clinical Trial.
99 results